Triumeq
Asset
Combines dolutegravir, abacavir and lamivudine to inhibit viral integrase and reverse transcriptase, suppressing retroviral replication.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Amyotrophic lateral sclerosis
Phase 2, Completed, NCT02868580, clinicaltrials.gov, Oct 25, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.